Guide pratique sur le MAP

↪ Fondation canadienne pour la santé vasculaire 26 13. Treat-Jacobson D, McDermott MM, Bronas UG, Campia U, Collins TC, Criqui MH, Gardner AW, Hiatt WR, Regensteiner JG, Rich K; American Heart Association Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Council on Cardiovascular and Stroke Nursing. Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scienti c Statement From the American Heart Association. Circulation. 2019 Jan 22;139(4):e10-e33 Section 6 1. Barraclough K, Bradbury A. Chronic limb threatening ischaemia. BMJ. 2018;360:j5460 2. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME. 2016 aha/acc guideline on the management of patients with lower extremity peripheral artery disease: A report of the american college of cardiology/ american heart association task force on clinical practice lines. Circulation . 2017;135:e726-e779 3. Meneses AL, Ritti-Dias RM, Parmenter B, Golledge J, Askew CD. Combined lower limb revascularisation and supervised exercise training for patients with peripheral arterial disease: A systematic review of randomised controlled trials. Sports Med . 2017;47:987-1002 4. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the fourier trial (further cardiovascular outcomes research with pcsk9 inhibition in subjects with elevated risk). Circulation . 2018;137:338-350 5. Strobl FF, Brechtel K, Schmehl J, Zeller T, Reiser MF, Claussen CD, Tepe G. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther . 2013;20:699-706 6. Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, Abola MT, Branch KRH, Keltai K, Bhatt DL, Verhamme P, Fox KAA, Cook-Bruns N, Lanius V, Connolly SJ, Yusuf S. Major adverse limb events and mortality in patients with peripheral artery disease: The compass trial. J Am Coll Cardiol . 2018;71:2306-2315 7. Zannad F, Greenberg B, Cleland JG, Gheorghiade M, van Veldhuisen DJ, Mehra MR, Anker SD, Byra WM, Fu M, Mills RM. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the ef cacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and signi cant coronary artery disease following an exacerbation of heart failure: The commander hf trial. Eur J Heart Fail . 2015;17:735-742 8. Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Rof M, Rother J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I, Group ESCSD. 2017 esc guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the european society for vascular surgery (esvs): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesendorsed by: The european stroke organization (eso)the task force for the diagnosis and treatment of peripheral arterial diseases of the european society of cardiology (esc) and of the european society for vascular surgery (esvs). Eur Heart J . 2018;39:763-816 9. Hussain MA, Wheatcroft M, Nault P, Lindsay TF, Bhatt DL, Anand SS, Verma S, and Al-Omran M. COMPASS for Vascular Surgeons: Practical Considerations. Curr Opin Cardiol. 2019 Mar;34(2):178-184.